Author(s): Dr Anes Yang, Unaccredited Dermatology Registrar, The Skin Hospital, Darlinghurst, Sydney, New South Wales, Australia; Dr Monisha Gupta, Senior Staff Specialist, Department of Dermatology, Liverpool Hospital, Senior Lecturer, University of New South Wales, Sydney, New South Wales, Australia. DermNet NZ Medical Editor: Dr Delwyn Dyall-Smith, Dermatologist, Wagga Wagga, NSW, Australia. DermNet New Zealand Editor in Chief: Adjunct Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. September 2018.
Chloroquine is a synthetic antimalarial medication that was first developed in 1934.
In addition to its antimalarial effects, chloroquine has been used extensively in rheumatology and dermatology since the 1950s.
Despite its early successes, the use of chloroquine has mostly been superseded by hydroxychloroquine, a safer hydroxylated analogue, and its availability is now limited.
Chloroquine has immunomodulatory and anti-inflammatory effects and may also have a photoprotective effect .
Chloroquine and hydroxychloroquine have the same indications and usage, although the dosage regimens are different. Head-to-head comparisons suggest similar responses with equivalent doses, but greater retinal toxicity with chloroquine .
In dermatology, antimalarials such as chloroquine are regarded as appropriate treatments for:
They are sometimes used to treat other inflammatory skin diseases .
Children below 6 years of age should not be given chloroquine due to the risk of overdose and acute toxicity.
The chloroquine dose should be reduced in patients with renal disease, as up to 70% of chloroquine is excreted unchanged in the urine. Chloroquine itself can cause reduced kidney function of up to 10% especially in those over 60 years of age. Renal impairment results in higher blood levels and therefore increased toxicity risk.
Chloroquine should be used with caution in patients with known porphyria cutanea tarda (PCT). Chloroquine can be used to treat PCT, but in a very low dose (125 mg twice weekly). 250 mg/d can trigger a porphyria crisis, which can be fatal.
Chloroquine is contraindicated where there is a known hypersensitivity to 4-aminoquinoline compounds.
Chloroquine crosses the placenta and is also found in low levels in breast milk, so pregnancy and lactation are often listed contraindications (see DermNet’s pages on drugs in pregnancy and on lactation and the skin). However, effects on the fetus and baby have been rarely reported and chloroquine has been continued when required for malaria.
Pre-existing retinopathy and other eye problems such as macular degeneration and cataracts make monitoring more difficult, and so can also be relative contraindications.
Although chloroquine can occasionally trigger a flare of psoriasis, this is not an absolute contraindication and the use of the drug should be decided in individual cases.
Chloroquine has similar pharmacokinetics to hydroxychloroquine. After identical doses, the tissue levels of chloroquine are 2.5 times those of hydroxychloroquine. Chloroquine is rapidly and almost completely absorbed from the bowel following oral administration.
Peak plasma concentrations are reached within 4–12 hours but it takes 4–6 weeks for plasma concentrations to stabilise. Therefore, it will take 2–3 months to see a therapeutic effect. Up to 70% is excreted unchanged through the kidneys and up to 40% is metabolised in the liver to an active metabolite.
Chloroquine binds to plasma proteins that are deposited in tissues such as the liver, spleen, kidney and lung. Chloroquine has a particularly high affinity for melanin-containing cells and hence there are very high levels of chloroquine in the skin (mainly epidermis) and retina. Chloroquine has a long half-life, which can vary between 74 hours and 50 days, depending on the cumulative dose.
The drug can remain in the skin for 6–7 months after cessation of therapy.
Chloroquine phosphate is dispensed as a 250 mg tablet, which is equivalent to 155 mg chloroquine base.
Long-term use should aim for < 2.3 mg/kg/d based on actual body weight. Given the tablet size, this usually means it needs to be used intermittently, that is, several times per week instead of daily.
Previously, the maximum daily dose was calculated on ideal body weight, and cumulative dose was recommended to be less than 460 g. These guidelines have been revised.
In PCT, the dose should not exceed 125 mg twice weekly.
Chloroquine is not marketed in Australia, where it is only available through the Special Access Scheme. It is no longer approved for use in New Zealand but may be available under Section 29. See Medsafe, unapproved medications.
No dosage adjustment is provided in the manufacturer’s labelling.
Creatinine clearance ≥ 10 mL/minute: No dosage adjustment is necessary.
Creatinine clearance < 10 mL/minute: Administer 50% of usual dose.
The two main ocular effects of chloroquine are corneal deposits (reversible) and retinal toxicity (irreversible).
Corneal deposits occur rapidly in 90% of patients on chloroquine. They are usually asymptomatic, however patients can experience transient halos and heightened light sensitivity.
Finding corneal deposits on examination does not mean chloroquine should be stopped.
Deposits are dose related, occurring 1–1.5 months after therapy is initiated and resolve after discontinuation of chloroquine.
Irreversible retinal toxicity causing bilateral bull’s-eye retinopathy from chloroquine has been recognised for many years. This is a late stage finding and should not be seen if regular monitoring is conducted. The high affinity of chloroquine for melanin-containing cells, such as those found in the retinal pigment epithelium, is hypothesised to be the cause.
Patients with antimalarial-induced retinal toxicity may not have any visual symptoms initially and will only develop clinical symptoms in the late stages.
Cessation of the drug when definite signs of early retinopathy are found is important as progression to vision loss is then rare. Chloroquine should only be ceased if there are definite signs of retinal toxicity. Possible toxicity should be reassessed after several months with continued drug use. Continued use of chloroquine after the findings of definite retinopathy results in irreversible visual damage including effects on visual acuity, peripheral vision, and night vision.
The retinopathy does not reverse, even with cessation of the chloroquine, and there is no treatment. The risk of retinal toxicity is highest with chloroquine compared to other antimalarials .
In 2016, with new scientific data, the American Academy of Ophthalmology revised the screening recommendations for patients to be commenced on chloroquine for greater than one year .
The two most important risk factors are duration of treatment and daily dose based on actual body weight, particularly a daily dose of chloroquine exceeding 2.3 mg/kg actual body weight.
Monitoring is of particular importance in those over 60 and in those with renal impairment.
Every patient planning to take chloroquine for at least 12 months should undergo a baseline ophthalmic examination within six months of commencing chloroquine and then annually. Fundal examination alone is not sufficient screening. Examination should involve automated visual fields and spectral domain optical coherence tomography (SD OCT) .
Chloroquine can cause:
Nausea, vomiting and diarrhoea are often transient or resolve with dose reduction. Symptoms can be minimised by taking the medication with food.
Haemolytic anaemia and reduced blood cell counts are very rare at recommended doses but may occasionally occur in patients with G6PD deficiency.
Neuromyopathy, myalgia and fatigue have been reported with chloroquine use. Care should therefore be taken in patients with myasthenia gravis and dermatomyositis.
The following medications should be reviewed when used concomitantly with chloroquine: digoxin, methotrexate, D-penicillamine, ciclosporin, beta blockers, amiodarone, penicillin, cimetidine, ritonavir, cholestyramine, antacids, aminoglycosides, corticosteroids, neostigmine, and physostigmine.
Smoking has been reported to inhibit the P450 enzyme system, decreasing the efficacy of chloroquine .
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.